Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety,
tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced
cancer.